Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Steven Coutre,Ian W. Flinn,Sven de Vos,Jacqueline C. Barrientos,Marshall T. Schreeder,Nina Wagner-Johnson,Jeff Porter Sharman,Thomas E. Boyd,Nathan Fowler,Lyndah Dreiling,Yeonhee Kim,Siddhartha Mitra,Kanti R. Rai,John P. Leonard,Richard R. Furman

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

2018

Steven Coutre
Ian W. Flinn
Sven de Vos
Jacqueline C. Barrientos
Marshall T. Schreeder
Nina Wagner-Johnson
Jeff Porter Sharman
Thomas E. Boyd
Nathan Fowler
Lyndah Dreiling
Yeonhee Kim
Siddhartha Mitra
Kanti R. Rai
John P. Leonard
Richard R. Furman

AbstractPhosphatidylinositol 3-kinase-delta (PI3Kδ) signaling is critical for proliferation, survival, homing, and tissue retention of malignant B cells. Idelalisib, a selective oral inhibitor of PI3Kδ, has shown considerable single-agent activity in patients with heavily pretreated chronic lymphocy

Keywords:

Refractory Chronic Lymphocytic Leukemia
Rituximab
Bendamustine
Oncology
Internal medicine
Medicine
Idelalisib
Cancer research
Chronic lymphocytic leukemia
relapsed refractory
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations